ArticlePancreas2026
Plasma Proteomics Identifies Potential Pancreatic Cancer Risk Indicators in Type 2 Diabetes.
Article in Pancreas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is associated with diabetes; however, few plasma biomarkers have sufficient sensitivity and specificity for early diagnosis of pancreatic cancer. Here, we constructed a cohort comprising healthy controls, patients with Type 2 Diabetes (T2DM), and patients with pancreatic cancer complicated by T2DM (PCDM) for plasma proteomic analysis. These analyses covered 92 inflammation-associated proteins and 92 tumor-immune-associated proteins. The plasma proteomic analysis revealed that the expression levels of multiple immunoinflammatory proteins were significantly elevated in PCDM. Moreover, with the complication of T2DM and pancreatic cancer, the correlation between plasma proteins in patients showed a downward trend, indicating the potential impact of complex interactions on plasma proteins. Summarily, our findings suggest that increased IL-8 and decreased TWEAK may indicate a higher risk of pancreatic cancer in diabetic patients. Although validation in a larger cohort is necessary, the analysis highlights differences in plasma protein profiles among patients. This study was done to provide a meaningful indicator for early plasma detection of pancreatic cancer in diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.